Physician profile
Christopher Cochran
NPI 1649359076
$1,627.79
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $402 · 2021: $671 · 2022: $275.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $322.93 | 2019-2022 | |
| Gilead Sciences, INC. | $283.16 | 2020-2022 | |
| Abbvie INC. | $144.51 | 2019-2022 | |
| Novo Nordisk INC | $124.27 | 2019-2020 | |
| Daiichi Sankyo INC. | $116.91 | 2021-2022 | |
| Abbott Laboratories | $95.75 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $93.03 | 2020-2022 | |
| Lilly USA, LLC | $72.25 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $68.40 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.68 | 2019-2021 | |
| Dexcom, INC. | $43.93 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.36 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $31.67 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $23.43 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $15.95 | 2022 | |
| Merck Sharp & Dohme LLC | $14.94 | 2021 | |
| Allergan, INC. | $14.68 | 2020 | |
| Vifor Pharma, INC. | $14.33 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.81 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.